Association of LDL-cholesterol subfractions with cardiovascular disorders: a systematic review.
Cardiovascular Disease
Cholesterol
LDL subclasses
Low-density lipoprotein
Small dense LDL
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
25
06
2023
accepted:
25
10
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
Cardiovascular disorders (CVDs) are the leading cause of death worldwide. This study aimed to evaluate the association between low-density lipoprotein (LDL) subfractions and cardiovascular disorders. To ensure the rigor of the systematic review, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used. For this systematic review, a comprehensive search strategy was performed in important databases including PubMed, Scopus, Embase, International Statistical Institute (ISI) Web of Science, and google scholar from 2009 to February 2021. The following terms were used for systematic search: low-density lipoprotein, LDL, subfractions, subclasses, nuclear magnetic resonance, NMR, chromatography, high-pressure liquid, HPLC, cardiovascular disease, cerebrovascular, and peripheral vascular disease. Also, for evaluating the risk of bias, the Newcastle-Ottawa scale was employed. At the end of the search process, 33 articles were included in this study. The results of most of the evaluated studies revealed that a higher LDL particle number was consistently associated with increased risk for cardiovascular disease, independent of other lipid measurements. Also, small dense LDL was associated with an increased risk of CVDs. There was no association between LDL subfraction and CVDs in a small number of studies. Overall, it seems that the evaluation of LDL subclasses can be used as a very suitable biomarker for the assessment and diagnosis of cardiovascular diseases. However, further studies are required to identify the mechanisms involved.
Sections du résumé
BACKGROUND
Cardiovascular disorders (CVDs) are the leading cause of death worldwide. This study aimed to evaluate the association between low-density lipoprotein (LDL) subfractions and cardiovascular disorders.
METHODS
To ensure the rigor of the systematic review, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used. For this systematic review, a comprehensive search strategy was performed in important databases including PubMed, Scopus, Embase, International Statistical Institute (ISI) Web of Science, and google scholar from 2009 to February 2021. The following terms were used for systematic search: low-density lipoprotein, LDL, subfractions, subclasses, nuclear magnetic resonance, NMR, chromatography, high-pressure liquid, HPLC, cardiovascular disease, cerebrovascular, and peripheral vascular disease. Also, for evaluating the risk of bias, the Newcastle-Ottawa scale was employed.
RESULTS
At the end of the search process, 33 articles were included in this study. The results of most of the evaluated studies revealed that a higher LDL particle number was consistently associated with increased risk for cardiovascular disease, independent of other lipid measurements. Also, small dense LDL was associated with an increased risk of CVDs. There was no association between LDL subfraction and CVDs in a small number of studies.
CONCLUSIONS
Overall, it seems that the evaluation of LDL subclasses can be used as a very suitable biomarker for the assessment and diagnosis of cardiovascular diseases. However, further studies are required to identify the mechanisms involved.
Identifiants
pubmed: 37914996
doi: 10.1186/s12872-023-03578-0
pii: 10.1186/s12872-023-03578-0
pmc: PMC10621218
doi:
Substances chimiques
Cholesterol, LDL
0
Lipoproteins, LDL
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533Informations de copyright
© 2023. The Author(s).
Références
Int J Clin Pract. 2021 Jan;75(1):e13610
pubmed: 32648987
Neuro Endocrinol Lett. 2011;32(3):317-21
pubmed: 21712790
N Engl J Med. 2006 Dec 21;355(25):2615-7
pubmed: 17182986
Am J Cardiol. 2002 Jul 15;90(2):89-94
pubmed: 12106834
Ann Intern Med. 2015 Jul 7;163(1):40-51
pubmed: 25915661
Int J Endocrinol Metab. 2018 Oct 16;16(4 Suppl):e84783
pubmed: 30584444
Curr Opin Cardiol. 2017 Jul;32(4):454-459
pubmed: 28426445
Thromb Haemost. 2021 May;121(5):676-686
pubmed: 33506473
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Bratisl Lek Listy. 2011;112(1):4-7
pubmed: 21452770
Annu Rev Nutr. 2001;21:283-95
pubmed: 11375438
Lancet. 1994 Sep 3;344(8923):633-8
pubmed: 7864934
Blood. 2016 Mar 10;127(10):1336-45
pubmed: 26679863
Diabetes Metab Res Rev. 2021 Jan;37(1):e3362
pubmed: 32515046
Neuro Endocrinol Lett. 2011;32(3):322-7
pubmed: 21712784
Atherosclerosis. 2010 Jun;210(2):548-54
pubmed: 20022325
J Rheumatol. 2010 Aug 1;37(8):1633-8
pubmed: 20516025
Yonsei Med J. 2006 Jun 30;47(3):405-14
pubmed: 16807992
Int J Cardiol. 2010 May 28;141(2):122-31
pubmed: 19910061
Ann Indian Acad Neurol. 2013 Oct;16(4):498-503
pubmed: 24339567
Lancet. 2019 Sep 28;394(10204):1145-1158
pubmed: 31248666
Heart Asia. 2012 Oct 16;4(1):141-5
pubmed: 27326051
Clin Endocrinol (Oxf). 2009 Jun;70(6):870-5
pubmed: 18771560
Am J Cardiol. 2002 Oct 17;90(8A):48i-54i
pubmed: 12419480
JAMA. 2016 Aug 16;316(7):743-53
pubmed: 27533159
J Lipid Res. 2002 Sep;43(9):1363-79
pubmed: 12235168
Atherosclerosis. 2018 Aug;275:390-399
pubmed: 29703634
BMC Neurol. 2020 Nov 13;20(1):414
pubmed: 33183255
Am J Cardiol. 2013 Jan 15;111(2):213-8
pubmed: 23141758
Anticancer Res. 2019 Nov;39(11):6035-6039
pubmed: 31704829
Curr Atheroscler Rep. 2008 Oct;10(5):377-85
pubmed: 18706278
J Clin Med. 2019 Nov 05;8(11):
pubmed: 31694246
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
J Clin Med. 2019 Feb 03;8(2):
pubmed: 30717448
Atherosclerosis. 2009 Aug;205(2):342-8
pubmed: 19162266
J Clin Lipidol. 2011 Sep-Oct;5(5):408-13
pubmed: 21981843
Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2181-7
pubmed: 15388521
J Lipid Res. 1991 Nov;32(11):1741-53
pubmed: 1770294
Sci Rep. 2018 Aug 8;8(1):11866
pubmed: 30089847
Am J Cardiol. 1995 Feb 23;75(6):53B-57B
pubmed: 7863975
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):448-54
pubmed: 25477346
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Ann Intern Med. 2009 Apr 7;150(7):474-84
pubmed: 19349632
Nat Rev Cardiol. 2014 Oct;11(10):563-75
pubmed: 24958078
Circulation. 2009 Feb 24;119(7):931-9
pubmed: 19204302
Lancet. 2012 Aug 11;380(9841):572-80
pubmed: 22607825
Atherosclerosis. 2017 Aug;263:287-292
pubmed: 28728064
J Clin Biochem Nutr. 2018 Sep;63(2):144-148
pubmed: 30279626
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
J Atheroscler Thromb. 2019 Jan 1;26(1):50-63
pubmed: 30224606
Am J Cardiol. 2002 Oct 17;90(8A):30i-47i
pubmed: 12419479
J Lipid Res. 2004 Jun;45(6):1069-76
pubmed: 14993238
Clin Chim Acta. 2012 Dec 24;414:215-24
pubmed: 22989852
N Engl J Med. 2006 Dec 21;355(25):2631-9
pubmed: 17182988